NorthWest Biotherapeutics Inc (NWBO)

[exwannabe]

Attacking management and timelines are low hanging fruit in BASHER land

The low hanging fruit is questioning a trial where they randomized 233 vs 99 and fail to disclose the trial's OS endpoint on that, especially when it looks like the 233 did not live as long numerically as the 99.

The low hanging fruit is questioning a trial that switched from randomized endpoints (the gold standard) to post hock comps to ECA's w/o even having patient ;level data. After knowing the results if the efficacy IA in 2015.

The low hanging fruit is questioning why they elect to file in the UK which has a very marginal market compared to US/EU.

Management issues hardly count.That is not fruit, it is like stepping on bugs. Even perma bull Doc Logic states that LP intentionally lies to get retail to put cash into the company.